Overview

Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning

Status:
Not yet recruiting

Trial end date:
2028-12-01

Target enrollment:

Participant gender:

Summary

Because the anti-leukemic activity of busulfan, this dug is largely used in graft conditioning but in elderly and/or cormobid patienth an excess of toxicity is observed. This study focus on the possibility of significanty reducing this toxicity by customizing the doses of busulfan to individual PK parameters.

Phase:

Phase 2

Details

Lead Sponsor:

Institut Paoli-Calmettes

Treatments:

Busulfan